HB 1638

The bill may reduce accountability for opioid prescribing by creating a legal safe harbor for providers who follow the consent requirement, potentially weakening oversight of high-risk prescribing practices. While the bill requires documented consent and medical appropriateness, it does not require objective risk assessment (e.g., urine testing, PDMP review), leaving providers with broad discretion to justify prescriptions in 'good faith'—a subjective standard that could be exploited even when clinical guidelines would discourage opioid use.

The bill creates a two-tiered standard: pharmacists must only confirm a prescription is 'valid' and that the patient received 'consultation' (no documented consent required), while prescribers must obtain documented consent. This asymmetry may reduce pharmacist vigilance in flagging potentially inappropriate prescriptions, as they face no requirement to assess medical appropriateness or patient risk beyond the paper prescription.

Patients with chronic pain may experience reduced access to non-opioid alternatives if providers, fearing liability, default to prescribing opioids under the new safe harbor rather than pursuing multimodal or non-pharmacologic pain management—especially if those alternatives require more time, coordination, or are less reimbursed. The bill’s emphasis on 'good faith' opioid prescribing may reinforce overreliance on opioids despite evolving clinical guidelines (e.g., CDC 2022) that recommend against opioids as first-line for chronic pain.

The bill’s reliance on 'written informed consent' as a proxy for patient understanding may be misleading: studies show that consent forms for opioids are often lengthy, jargon-heavy, and poorly understood by patients—especially those with low health literacy, limited English proficiency, or cognitive impairment. This could create a legal fiction of informed consent without meaningful patient engagement, undermining true autonomy and potentially masking coercion or pressure to accept opioids.

The bill does not require providers to document pain assessment, functional goals, risk stratification, or treatment agreement—core elements of responsible opioid prescribing per CDC and Washington State Medical Quality Assurance Commission (MQAC) guidelines. Without these, 'medical appropriateness' and 'good faith' become self-certified, increasing risk of inappropriate long-term opioid therapy and associated harms (addiction, overdose, misuse).